AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 11726254 — intervention group
Group type: COMPARATOR
Intervention: Control group (CTL)
Number of subjects: 20
Study 9355081 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction therapy with antilymphocyte antibodies
Number of subjects: 7
Study 9355081 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy (cyclosporine, azathioprine, and prednisone)
Number of subjects: 7
Study 9355081 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction therapy
Number of subjects: 7
Study 8202978 — intervention group
Group type: EXPERIMENTAL
Intervention: Electromyographic biofeedback treatment together with physical therapy
Number of subjects: 16
Study 8202978 — intervention group
Group type: COMPARATOR
Intervention: Physical therapy only
Number of subjects: 16
Study 3098555 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepine (CBZ)
Number of subjects: 39
Study 3098555 — intervention group
Group type: COMPARATOR
Intervention: Phenobarbital (PB)
Number of subjects: 39
Study 31743282 — intervention group
Group type: EXPERIMENTAL
Intervention: CGRP expression in blind, painful eyes (n=8)
Number of subjects: 8
Study 31743282 — intervention group
Group type: COMPARATOR
Intervention: Control group (nonpainful enucleated eyes)
Number of subjects: 8
Study 30845958 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-level intervention combining implementation science and community-based participatory research approaches; includes optimization of acute stroke care in emergency departments and community-wide workshops led by peer educators over 2 years.
Number of subjects: 0
Study 27889390 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 mg GSE
Number of subjects: 29
Study 27889390 — intervention group
Group type: EXPERIMENTAL
Intervention: 1500 mg GSE
Number of subjects: 29
Study 27889390 — intervention group
Group type: EXPERIMENTAL
Intervention: 2500 mg GSE
Number of subjects: 29
Study 25214069 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoledronic acid (ZOL) 5 mg annually for up to three injections (years 4, 5, and 6)
Number of subjects: 1223
Study 25214069 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 3 years (years 1, 2, and 3)
Number of subjects: 1223
Study 25214069 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoledronic acid (ZOL)
Number of subjects: 1223
Study 23739813 — intervention group
Group type: COMPARATOR
Intervention: Low dose (0.00375 mmol/kg)
Number of subjects: 18
Study 23739813 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium dose (0.0075 mmol/kg)
Number of subjects: 18
Study 23739813 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose (0.0150 mmol/kg)
Number of subjects: 18
Study 21524238 — intervention group
Group type: EXPERIMENTAL
Intervention: naproxen/esomeprazole magnesium
Number of subjects: 1234
Study 21524238 — intervention group
Group type: EXPERIMENTAL
Intervention: celecoxib
Number of subjects: 1234
Study 18813412 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginger capsules 3 g/day in 3 divided doses for 45 days
Number of subjects: 85
Study 18813412 — intervention group
Group type: COMPARATOR
Intervention: Placebo (lactose capsule 3 g/day in 3 divided doses for 45 days)
Number of subjects: 85
Study 17059329 — intervention group
Group type: EXPERIMENTAL
Intervention: RT-PCR using MMG marker
Number of subjects: 59
Study 17059329 — intervention group
Group type: EXPERIMENTAL
Intervention: RT-PCR using CEA marker
Number of subjects: 59
Study 17059329 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of MMG and CEA markers
Number of subjects: 59
Study 15312092 — intervention group
Group type: EXPERIMENTAL
Intervention: Machined surface implants
Number of subjects: 51
Study 15312092 — intervention group
Group type: EXPERIMENTAL
Intervention: Rough-surface Tioblast implants
Number of subjects: 51
Study 15312092 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall failure rate
Number of subjects: 51
Study 15312092 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiographic signs of loss of osseointegration
Number of subjects: 51
Study 11269585 — intervention group
Group type: EXPERIMENTAL
Intervention: Preconditioned patellar tendon autograft (group P)
Number of subjects: 53
Study 11269585 — intervention group
Group type: COMPARATOR
Intervention: No preconditioning (group NP)
Number of subjects: 53
Study 9313757 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose intravenous insulin infusion (1.2 +/- 0.4 U.kg‐1.day‐1)
Number of subjects: 19
Study 9313757 — intervention group
Group type: COMPARATOR
Intervention: Intensive insulin therapy (0.4 +/- 0.1 U.kg‐1.day‐1)
Number of subjects: 19
Study 9313757 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose intravenous insulin infusion
Number of subjects: 19
Study 9313757 — intervention group
Group type: COMPARATOR
Intervention: Intensive insulin therapy
Number of subjects: 19
Study 9313757 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose intravenous insulin infusion and Intensive insulin therapy
Number of subjects: 19
Study 8337206 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-monitoring of diet
Number of subjects: 314
Study 8337206 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-monitoring of exercise
Number of subjects: 314
Study 8337206 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-monitoring of aerobic physical activity
Number of subjects: 314
Study 3780088 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraarticular methylprednisolone (40 mg)
Number of subjects: 98
Study 3780088 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 98
Study 30048006 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 repeated intrathecal injections of autologous bone marrow–derived mesenchymal stem cells (BM‐MSCs)
Number of subjects: 64
Study 30048006 — intervention group
Group type: COMPARATOR
Intervention: riluzole alone
Number of subjects: 64
Study 27797708 — intervention group
Group type: EXPERIMENTAL
Intervention: Hesperidin 2S (450 mg/d)
Number of subjects: 68
Study 27797708 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study 24325594 — intervention group
Group type: EXPERIMENTAL
Intervention: Constraint‐induced movement therapy (CIMT) program
Number of subjects: 30
Study 24325594 — intervention group
Group type: COMPARATOR
Intervention: Conventional non‐structured therapy program (control group)
Number of subjects: 30
Study 22890117 — intervention group
Group type: COMPARATOR
Intervention: S(+)‐ketamine (20 mg/70 kg for the first hour, 40 mg/70 kg for the second hour)
Number of subjects: 12
Study 22890117 — intervention group
Group type: COMPARATOR
Intervention: S(+)‐ketamine
Number of subjects: 12
Study 19880291 — intervention group
Group type: EXPERIMENTAL
Intervention: Olive oil-based lipid emulsion
Number of subjects: 36
Study 19880291 — intervention group
Group type: COMPARATOR
Intervention: Long-chain triacylglycerols
Number of subjects: 36
Study 19880291 — intervention group
Group type: COMPARATOR
Intervention: Medium-chain/long-chain triacylglycerols
Number of subjects: 36
Study 17912634 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole
Number of subjects: 0
Study 17912634 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen
Number of subjects: 0
Study 16212446 — intervention group
Group type: EXPERIMENTAL
Intervention: clinic-directed group, replicating the parameters of the early intensive behavioral treatment developed at UCLA
Number of subjects: 24
Study 16212446 — intervention group
Group type: COMPARATOR
Intervention: parent-directed group that received intensive hours but less supervision
Number of subjects: 24
Study 16212446 — intervention group
Group type: EXPERIMENTAL
Intervention: combined groups
Number of subjects: 24
Study 12070712 — intervention group
Group type: EXPERIMENTAL
Intervention: GM-CSF/IL-2
Number of subjects: 20
Study 12070712 — intervention group
Group type: COMPARATOR
Intervention: GM-CSF
Number of subjects: 20
Study 10951234 — intervention group
Group type: EXPERIMENTAL
Intervention: Aminolevulinic acid plus red light
Number of subjects: 22
Study 10951234 — intervention group
Group type: EXPERIMENTAL
Intervention: Aminolevulinic acid alone
Number of subjects: 22
Study 10951234 — intervention group
Group type: EXPERIMENTAL
Intervention: Light alone
Number of subjects: 22
Study 10951234 — intervention group
Group type: COMPARATOR
Intervention: Untreated control
Number of subjects: 22
Study 8828743 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV RNA levels
Number of subjects: 620
Study 8828743 — intervention group
Group type: EXPERIMENTAL
Intervention: CD4 count
Number of subjects: 620
Study 8828743 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV RNA levels and CD4 count (multiple regression model)
Number of subjects: 620
Study 1446477 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased inhaled corticosteroid (mean 1478 micrograms daily)
Number of subjects: 32
Study 1446477 — intervention group
Group type: COMPARATOR
Intervention: Regular inhaled bronchodilator (on-demand beta-agonist)
Number of subjects: 32
Study 3913273 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25% timolol maleate (Blocanol)
Number of subjects: 57
Study 3913273 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% timolol maleate (Blocanol)
Number of subjects: 57
Study 3913273 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25% timolol maleate (Oftan‐Timolol)
Number of subjects: 57
Study 3913273 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% timolol maleate (Oftan‐Timolol)
Number of subjects: 57
Study 31601479 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate exercise (IE, during taxane chemotherapy)
Number of subjects: 27
Study 31601479 — intervention group
Group type: COMPARATOR
Intervention: Delayed exercise (DE, after chemotherapy)
Number of subjects: 27
Study 28677088 — intervention group
Group type: EXPERIMENTAL
Intervention: Technical assistance providers rated their collaborative relationship with their teams
Number of subjects: 14
Study 28677088 — intervention group
Group type: EXPERIMENTAL
Intervention: Community readiness
Number of subjects: 14
Study 28677088 — intervention group
Group type: EXPERIMENTAL
Intervention: Team differences in change during the implementation phase
Number of subjects: 14
Study 27391951 — intervention group
Group type: EXPERIMENTAL
Intervention: Canagliflozin 100 mg
Number of subjects: 1856
Study 27391951 — intervention group
Group type: EXPERIMENTAL
Intervention: Canagliflozin 300 mg
Number of subjects: 1856
Study 27391951 — intervention group
Group type: COMPARATOR
Intervention: Sitagliptin 100 mg
Number of subjects: 1856
Study 24767613 — intervention group
Group type: EXPERIMENTAL
Intervention: Uncued walking (elderly)
Number of subjects: 41
Study 24767613 — intervention group
Group type: EXPERIMENTAL
Intervention: Regularly cued walking (young)
Number of subjects: 41
Study 24767613 — intervention group
Group type: EXPERIMENTAL
Intervention: Irregularly cued walking (young)
Number of subjects: 41
Study 24767613 — intervention group
Group type: EXPERIMENTAL
Intervention: Regularly cued walking (higher executive function)
Number of subjects: 41
Study 24767613 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking conditions (lower executive function)
Number of subjects: 41
Study 22698825 — intervention group
Group type: EXPERIMENTAL
Intervention: MRSA positive patients
Number of subjects: 190
Study 22698825 — intervention group
Group type: COMPARATOR
Intervention: Non-MRSA patients
Number of subjects: 190
Study 22698825 — intervention group
Group type: EXPERIMENTAL
Intervention: Abscess size ≥ 5 cm
Number of subjects: 190
Study 22698825 — intervention group
Group type: EXPERIMENTAL
Intervention: Abscess size < 5 cm
Number of subjects: 190
Study 22698825 — intervention group
Group type: EXPERIMENTAL
Intervention: Cellulitis size ≥ 5 cm
Number of subjects: 190
Study 22698825 — intervention group
Group type: EXPERIMENTAL
Intervention: Cellulitis size < 5 cm
Number of subjects: 190
Study 22698825 — intervention group
Group type: EXPERIMENTAL
Intervention: Larger abscesses
Number of subjects: 190
Study 22698825 — intervention group
Group type: EXPERIMENTAL
Intervention: Smaller abscesses
Number of subjects: 190
Study 22698825 — intervention group
Group type: EXPERIMENTAL
Intervention: Larger cellulitis
Number of subjects: 190
Study 22698825 — intervention group
Group type: EXPERIMENTAL
Intervention: Smaller cellulitis
Number of subjects: 190
Study 20545916 — intervention group
Group type: EXPERIMENTAL
Intervention: PLACE HIV prevention intervention
Number of subjects: 2859
Study 20545916 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 2859
Study 18568885 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical ketorolac
Number of subjects: 32
Study 18568885 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ketorolac
Number of subjects: 32
Study 18568885 — intervention group
Group type: COMPARATOR
Intervention: Oral placebo
Number of subjects: 32
Study 18568885 — intervention group
Group type: COMPARATOR
Intervention: Topical placebo
Number of subjects: 32
Study 15750426 — intervention group
Group type: EXPERIMENTAL
Intervention: FDBA plus PRP
Number of subjects: 10
Study 15750426 — intervention group
Group type: COMPARATOR
Intervention: FDBA plus membrane
Number of subjects: 10
Study 12087928 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed combination capsule of chloroquine (100 mg) and proguanil (200 mg)
Number of subjects: 12
Study 12087928 — intervention group
Group type: COMPARATOR
Intervention: Separate tablets of chloroquine (100 mg) and proguanil (200 mg)
Number of subjects: 12
Study 12087928 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed combination capsule of chloroquine and proguanil
Number of subjects: 12
Study 12087928 — intervention group
Group type: COMPARATOR
Intervention: Separate tablets of chloroquine and proguanil
Number of subjects: 12
Study 10480474 — intervention group
Group type: EXPERIMENTAL
Intervention: Morning dosing of nisoldipine ER (20 mg)
Number of subjects: 85
Study 10480474 — intervention group
Group type: EXPERIMENTAL
Intervention: Evening dosing of nisoldipine ER (20 mg)
Number of subjects: 85
Study 8726542 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropinirole
Number of subjects: 46
Study 8726542 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 30822800 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal pain management protocol (preoperative intravenous acetaminophen, preincision subcutaneous bupivacaine, intraoperative intramuscular ketorolac)
Number of subjects: 120
Study 30822800 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 30822800 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal pain management protocol
Number of subjects: 120
Study 28325826 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyphenon E (800 or 1200 mg of EGCG)
Number of subjects: 31
Study 27275271 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT) with 970 nm diode laser irradiation
Number of subjects: 24
Study 27275271 — intervention group
Group type: COMPARATOR
Intervention: Topical corticosteroids (0.1% triamcinolone acetonide orabase)
Number of subjects: 24
Study 25693307 — intervention group
Group type: EXPERIMENTAL
Intervention: 11 needles
Number of subjects: 90
Study 25693307 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 needles
Number of subjects: 90
Study 25693307 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 needles
Number of subjects: 90
Study 22949766 — intervention group
Group type: EXPERIMENTAL
Intervention: Subxiphoid approach (Group 1, n=20)
Number of subjects: 40
Study 22949766 — intervention group
Group type: COMPARATOR
Intervention: Intercostal approach (Group 2, n=20)
Number of subjects: 40
Study 18506401 — intervention group
Group type: EXPERIMENTAL
Intervention: Sealant (Light Bond) applied to labial surfaces
Number of subjects: 78
Study 18506401 — intervention group
Group type: COMPARATOR
Intervention: Control group with no sealant
Number of subjects: 78
Study 16430195 — intervention group
Group type: EXPERIMENTAL
Intervention: Peramivir 400 mg q24h
Number of subjects: 288
Study 16430195 — intervention group
Group type: EXPERIMENTAL
Intervention: Peramivir 200 mg q12h
Number of subjects: 288
Study 16430195 — intervention group
Group type: EXPERIMENTAL
Intervention: Peramivir 400 mg once daily
Number of subjects: 288
Study 16430195 — intervention group
Group type: EXPERIMENTAL
Intervention: Peramivir 800/400 mg once daily
Number of subjects: 288
Study 16430195 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 288
Study 16430195 — intervention group
Group type: EXPERIMENTAL
Intervention: Peramivir 50 mg
Number of subjects: 288
Study 16430195 — intervention group
Group type: EXPERIMENTAL
Intervention: Peramivir 200 mg
Number of subjects: 288
Study 16430195 — intervention group
Group type: EXPERIMENTAL
Intervention: Peramivir 400 mg
Number of subjects: 288
Study 16430195 — intervention group
Group type: EXPERIMENTAL
Intervention: Peramivir 800 mg
Number of subjects: 288
Study 12952257 — intervention group
Group type: EXPERIMENTAL
Intervention: nCPAP with heated humidification (nCPAP‐humid)
Number of subjects: 42
Study 12952257 — intervention group
Group type: COMPARATOR
Intervention: nCPAP placebo humidification (nCPAP pl‐humid)
Number of subjects: 42
Study 11098580 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous blood transfusion
Number of subjects: 0
Study 11098580 — intervention group
Group type: EXPERIMENTAL
Intervention: Leucocyte-depleted blood transfusion
Number of subjects: 0
Study 11098580 — intervention group
Group type: COMPARATOR
Intervention: Conventional allogeneic transfusion
Number of subjects: 0
Study 8782736 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) replacement therapy
Number of subjects: 46
Study 1635122 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiotepa
Number of subjects: 356
Study 1635122 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Number of subjects: 356
Study 1635122 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin
Number of subjects: 356
Study 6364892 — intervention group
Group type: EXPERIMENTAL
Intervention: cyclandelate 400 mg qid
Number of subjects: 12
Study 6364892 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 12
Study 31464391 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral nutritional supplementation (ONS) with dietary guidance
Number of subjects: 114
Study 31464391 — intervention group
Group type: COMPARATOR
Intervention: Dietary guidance only (Control)
Number of subjects: 114
Study 31464391 — intervention group
Group type: EXPERIMENTAL
Intervention: ONS
Number of subjects: 114
Study 31464391 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 114
Study 30015629 — intervention group
Group type: EXPERIMENTAL
Intervention: L-rhamnose (25 g d-1)
Number of subjects: 10
Study 30015629 — intervention group
Group type: COMPARATOR
Intervention: Inulin
Number of subjects: 10
Study 30015629 — intervention group
Group type: COMPARATOR
Intervention: Cellulose
Number of subjects: 10
Study 30015629 — intervention group
Group type: EXPERIMENTAL
Intervention: L-rhamnose
Number of subjects: 10
Study 26996096 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical pathway of care with guideline-based advice and exercise (up to three sessions) for low-risk participants; referral to a specialist for medium/high-risk participants
Number of subjects: 236
Study 26996096 — intervention group
Group type: COMPARATOR
Intervention: Usual care provided by primary healthcare provider based on clinical judgment
Number of subjects: 236
Study 24610876 — intervention group
Group type: EXPERIMENTAL
Intervention: Seropositive for HPV-16 antibodies
Number of subjects: 16656
Study 24610876 — intervention group
Group type: EXPERIMENTAL
Intervention: Seropositive for HPV-18 antibodies
Number of subjects: 16656
Study 24610876 — intervention group
Group type: COMPARATOR
Intervention: Seronegative women (control group)
Number of subjects: 16656
Study 22932751 — intervention group
Group type: EXPERIMENTAL
Intervention: PTH 1‐34 (30 μg/kg daily intraperitoneal injections for 14 days)
Number of subjects: 0
Study 22932751 — intervention group
Group type: COMPARATOR
Intervention: Control (saline injections)
Number of subjects: 0
Study 21221502 — intervention group
Group type: EXPERIMENTAL
Intervention: Food supplements
Number of subjects: 100
Study 21221502 — intervention group
Group type: COMPARATOR
Intervention: Control group (no food supplements)
Number of subjects: 100
Study 19453774 — intervention group
Group type: EXPERIMENTAL
Intervention: Rupatadine 10 mg
Number of subjects: 538
Study 19453774 — intervention group
Group type: EXPERIMENTAL
Intervention: Rupatadine 20 mg
Number of subjects: 538
Study 19453774 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 538
Study 16435700 — intervention group
Group type: EXPERIMENTAL
Intervention: Display type (icon and file name)
Number of subjects: 10
Study 16435700 — intervention group
Group type: EXPERIMENTAL
Intervention: Display organization (arrangements with and without grouping)
Number of subjects: 10
Study 16435700 — intervention group
Group type: EXPERIMENTAL
Intervention: Number of stimuli presented (4, 8, and 16)
Number of subjects: 10
Study 16435700 — intervention group
Group type: EXPERIMENTAL
Intervention: Display layout complexity
Number of subjects: 10
Study 12907547 — intervention group
Group type: EXPERIMENTAL
Intervention: Snoring
Number of subjects: 974
Study 10470203 — intervention group
Group type: EXPERIMENTAL
Intervention: Monoclonal antibody-based assay for TPA (TPA-M)
Number of subjects: 0
Study 10470203 — intervention group
Group type: COMPARATOR
Intervention: Polyclonal-based assay for TPA
Number of subjects: 0
Study 8735197 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluorescence polarization immunoassays (FPIA) from Abbott Laboratories for the analysis of amphetamines
Number of subjects: 0
Study 8735197 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of immunological assays with different antibodies
Number of subjects: 0
Study 8735197 — intervention group
Group type: EXPERIMENTAL
Intervention: Chromatographic methods
Number of subjects: 0
Study 1662882 — intervention group
Group type: EXPERIMENTAL
Intervention: Temafloxacin 200 or 400 mg once daily for 3 or 7 days
Number of subjects: 555
Study 1662882 — intervention group
Group type: COMPARATOR
Intervention: Control regimen (trimethoprim/sulfamethoxazole 160 mg/800 mg, ciprofloxacin 250 mg, or norfloxacin 400 mg, each given twice daily for 7-10 days)
Number of subjects: 555
Study 7082776 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg oral tablet
Number of subjects: 0
Study 7082776 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg intramuscular injection
Number of subjects: 0
Study 7082776 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg intramuscular injection
Number of subjects: 0
Study 7082776 — intervention group
Group type: COMPARATOR
Intervention: 10 mg intravenous injection
Number of subjects: 0
Study 31931172 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral anticoagulant (OAC) treatment
Number of subjects: 84521